Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type <i>EGFR</i>
Cited by 12
Related Papers
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
|Molecular Cancer|2019|316
Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma
|Molecular Cancer Therapeutics|2014|83